Science
Adagrasib , Jordi Remon PECATI Trial
Jordi Remon/X

Jordi Remon: PECATI Trial – Lenvatinib Plus Pembrolizumab in Metastatic B3-Thymoma and Thymic Carcinoma

Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:

“PECATI Trial, lenvatinib plus pembrolizumab (20/200) a potential ttx for patients with metastatic pretreated B3-Thymoma or TC.

  • mPFS 14.9mo
  • ORR: 23.3%
  • 1-y OS: 85.2%
  • G3 irAEs: 14%
  • Keep Dose intensity lenva first 8 weeks high PFS

Thanks to all authors!!”

Title: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study

Authors: Elena Elimova, Jaffer Ajani, Howard Burris, Crystal S Denlinger, Yoon-Koo Kang, Jwa Hoon Kim, Keun-Wook Lee, Bruce Lin, Rutika Mehta, Do-Youn Oh, Sun Young Rha, Young Mi Seol, Lin Yang, Mark A Ozog, Phillip M Garfin, Geoffrey Ku

Read The Full Article at The Lancet Oncology.

Jordi Remon: PECATI Trial - Lenvatinib Plus Pembrolizumab in Metastatic B3-Thymoma and Thymic Carcinoma

Read Further on OncoDaily: New Paper Alert: Zanidatamab Plus Chemotherapy for HER2-Positive Gastro-Oesophageal Adenocarcinoma

Bruce Lin cancer Crystal S. Denlinger Do-Youn Oh Elena Elimova Geoffrey Ku Howard Burris Jaffer Ajani Jordi Remon Jwa Hoon Kim Keun-Wook Lee Lin Yang Mark A. Ozog OncoDaily Oncology Phillip M. Garfin Rutika Mehta Sun Young Rha The Lancet Oncology Yoon-Koo Kang Young Mi Seol